These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 22989073)

  • 1. Author reply to Holford, Vu and Nutt regarding 'Piecing together the puzzle of progression and mortality in Parkinson's disease'.
    Marras C; Oakes D
    Br J Clin Pharmacol; 2013 May; 75(5):1372. PubMed ID: 22989073
    [No Abstract]   [Full Text] [Related]  

  • 2. Authors' response to Marras and Oakes, 'Piecing together the puzzle of progression and mortality in Parkinson's disease'.
    Holford NH; Vu TC; Nutt JG
    Br J Clin Pharmacol; 2013 May; 75(5):1370-1. PubMed ID: 22989096
    [No Abstract]   [Full Text] [Related]  

  • 3. Piecing together the puzzle of progression and mortality in Parkinson's disease.
    Marras C; Oakes D
    Br J Clin Pharmacol; 2012 Aug; 74(2):264-6. PubMed ID: 22554391
    [No Abstract]   [Full Text] [Related]  

  • 4. Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease.
    Vu TC; Nutt JG; Holford NH
    Br J Clin Pharmacol; 2012 Aug; 74(2):284-95. PubMed ID: 22300470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of motor and nonmotor features of Parkinson's disease and their response to treatment.
    Vu TC; Nutt JG; Holford NH
    Br J Clin Pharmacol; 2012 Aug; 74(2):267-83. PubMed ID: 22283961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [PSYCHOPHARMACOLOGY OF ANTIPARKINSONIAN DRUGS].
    Arushanyan EB; Naumov SS
    Eksp Klin Farmakol; 2017; 80(1):32-38. PubMed ID: 29874001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    Neurology; 1998 Feb; 50(2):573-4. PubMed ID: 9484410
    [No Abstract]   [Full Text] [Related]  

  • 8. Levodopa and the progression of Parkinson's disease.
    Walton-Hadlock JL
    N Engl J Med; 2005 Mar; 352(13):1386; author reply 1386. PubMed ID: 15800240
    [No Abstract]   [Full Text] [Related]  

  • 9. Drugs for Parkinson's disease.
    Med Lett Drugs Ther; 2017 Nov; 59(1534):187-194. PubMed ID: 29136401
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison table: drugs for Parkinson's disease.
    Med Lett Drugs Ther; 2017 Nov; 59(1534):e194-e196. PubMed ID: 29136402
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of early Parkinson's disease. Part 2.
    Simuni T; Lyons KE; Pahwa R; Hauser RA; Comella C; Elmer L; Weintraub D
    Eur Neurol; 2009; 61(4):206-15. PubMed ID: 19176961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia.
    Litvinenko IV; Odinak MM; Mogil'naya VI; Perstnev SV
    Neurosci Behav Physiol; 2010 Feb; 40(2):149-55. PubMed ID: 20033305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of levodopa therapy on motor function after posteroventral pallidotomy for Parkinson's disease.
    Linazasoro G; Obeso JA; Gorospe A; Rodríguez MC; Guridi J; Ramos E
    Neurology; 2000 Jan; 54(2):535-6. PubMed ID: 10668742
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study.
    Zibetti M; Merola A; Ricchi V; Marchisio A; Artusi CA; Rizzi L; Montanaro E; Reggio D; De Angelis C; Rizzone M; Lopiano L
    J Neurol; 2013 Jan; 260(1):105-14. PubMed ID: 22772358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safinamide (Xadago) for Parkinson's disease.
    Med Lett Drugs Ther; 2017 Sep; 59(1529):151-153. PubMed ID: 28880847
    [No Abstract]   [Full Text] [Related]  

  • 16. Medical treatment of Parkinson disease.
    Stacy M
    Neurol Clin; 2009 Aug; 27(3):605-31, v. PubMed ID: 19555824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future of pharmacogenetics in Parkinson's disease treatment.
    Hutz MH; Rieder CR
    Pharmacogenomics; 2018 Feb; 19(3):171-174. PubMed ID: 29191064
    [No Abstract]   [Full Text] [Related]  

  • 18. Gabapentin and motor fluctuations in Parkinson's disease.
    Chaná P; de Marinis A; Barrientos N
    Mov Disord; 1997 Jul; 12(4):608. PubMed ID: 9251083
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug therapy for Parkinson's disease.
    Hermanowicz N
    Semin Neurol; 2007 Apr; 27(2):97-105. PubMed ID: 17390254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive improvement during Tolcapone treatment in Parkinson's disease.
    Gasparini M; Fabrizio E; Bonifati V; Meco G
    J Neural Transm (Vienna); 1997; 104(8-9):887-94. PubMed ID: 9451720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.